ACTON, Mass. - Insulet (NASDAQ:PODD) Corporation (NASDAQ: PODD), known for its Omnipod brand of tubeless insulin pump technology, has announced positive outcomes from its first randomized controlled trial (RCT) of the Omnipod 5 Automated Insulin Delivery System for type 1 diabetes management. The findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.
The trial, involving 194 adult participants with type 1 diabetes from the United States and France, compared the Omnipod 5 system to traditional insulin pump therapy combined with continuous glucose monitoring (CGM).
The study focused on individuals with baseline HbA1c levels above 8%, with a mean of 8.5%. Over 13 weeks, the group using Omnipod 5 showed a 17.5% improvement in time in range (70-180 mg/dL), a significant reduction in HbA1c by 0.58%, and decreased time in both hypoglycemia and hyperglycemia.
Professor Eric Renard of Montpellier University Hospital highlighted the system's safety and efficacy, noting a profound impact on international accessibility and affordability. Insulet's Senior Vice President and Medical Director, Dr. Trang Ly, emphasized the trial's demonstration of Omnipod 5's benefits over standard therapies.
The trial also reported positive patient feedback, with significant improvements in diabetes distress, hypoglycemia confidence, and quality of life metrics. These results, which will be submitted for publication later this year, suggest Omnipod 5 as a first-line therapy for adults with type 1 diabetes.
Insulet Corporation, headquartered in Massachusetts, is committed to simplifying life for those with diabetes through its innovative Omnipod product platform. The Omnipod 5 system, which integrates with a CGM, offers a needle-free, non-stop insulin delivery method that can be managed via a smartphone or a dedicated controller.
The information in this article is based on a press release statement from Insulet Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.